FilingSEC EDGAR8-K
NeOnc Technologies Reports Q3 2026 Results and Clinical Progress
· SEC accepted
StagePhase 2a
Filing content
NeOnc Technologies reported a reduced Q3 net loss, completed a $15 million financing, and redeemed all outstanding Series A Convertible Preferred Stock, while preparing for upcoming clinical data presentations.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…